Recordati SpA Az nom Post raggruppamento REC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €52.80
- Day Range
- €52.50–52.85
- 52-Week Range
- €43.76–55.15
- Bid/Ask
- €52.00 / €53.00
- Shares Outstanding
- 204.81M
- Market Cap
- €10.75B
- Volume/Avg
- 151,630 / 387,486
Key Statistics
- Price/Earnings (Normalized)
- 19.77
- Price/Sales
- 4.05
- Dividend Yield (Trailing)
- 2.55%
- Dividend Yield (Forward)
- 2.70%
- Total Yield
- 2.96%
Company Profile
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 4,700
- Website
- https://www.recordati.com
Valuation
|
Metric
|
REC
|
|---|---|
Price/Earnings (Normalized) | 19.77 |
Price/Book Value | 5.05 |
Price/Sales | 4.05 |
Price/Cash Flow | 13.77 |
Price/Earnings
REC
Financial Strength
|
Metric
|
REC
|
|---|---|
Quick Ratio | 0.84 |
Current Ratio | 1.26 |
Interest Coverage | 7.83 |
Quick Ratio
REC
Profitability
|
Metric
|
REC
|
|---|---|
Return on Assets (Normalized) | 12.74% |
Return on Equity (Normalized) | 33.97% |
Return on Invested Capital (Normalized) | 16.93% |
Return on Assets
REC
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#q>bSBF | LOCK|j!V | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|FrLK%g | LOCK|Rm& | $627B | |||
| AbbVie Inc
ABBV
| LOCK|!BT$#$@ | LOCK|<X? | $441B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|CGqBJ$r | LOCK|$<X | $348B | |||
| Merck & Co Inc
MRK
| LOCK|bg!zRy | LOCK|@c | $335B | |||
| Novartis AG ADR
NVS
| LOCK|%Z?&X<X$ | LOCK|r$b | $286B | |||
| AstraZeneca PLC
AZN
| LOCK|G^k^XCWS | LOCK|&N | $240B | |||
| Amgen Inc
AMGN
| LOCK|l$T^K?<k | LOCK|v! | $224B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|w>Fw#T | LOCK|>F | $201B | |||
| Gilead Sciences Inc
GILD
| LOCK|jgr$!gY | LOCK|XQ | $172B |
United States